Glucocerebrosidase Gene Transfer to the Nervous System
葡萄糖脑苷脂酶基因转移至神经系统
基本信息
- 批准号:6642183
- 负责人:
- 金额:$ 19.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-08-07 至 2005-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The neuronopathic types of Gaucher disease still present a challenge for the treatment of the CNS symptoms. One approach would be gene therapy, but despite the fact that the glucocerebrosidase (GC) cDNA has been successfully transferred by retroviral vector to normal murine and human hematopoietic stem cells or by adeno-associated virus vector to muscle cells, and the transduced murine cells successfully transplanted in mice, the three clinical trials conducted to date resulted in either low levels of gene transfer, or a failure of engraftment after infusion, with a single exception. Gene transfer to neurons has been successfully demonstrated using retroviral, lentiviral, and other vectors. Engraftment of transduced neuronal and hematopoietic progenitors has been demonstrated in the brain of recipient animals. We hypothesize that transplantation of hematopoietic or neuronal progenitor cells transduced by retroviral and lentiviral vectors containing the cDNA for human glucocerebrosidase. This study will test the hypothesis that transplantation of hematopoietic or neuronal progenitor cells transduced by retroviral and lentiviral vectors containing the cDNA for human glucocerebrosidase will engraft in recipient Gaucher L444P mutant mice and lead to improved enzyme levels. Gene transfer to neurons has been successfully demonstrated with both retroviral and lentiviral vectors, and engraftment of transduced neuronal and hematopoietic progenitors has been attained in the brains of recipient animals. However, despite this success in animal models, the three clinical trials conducted to date have generally resulted in either low levels of gene transfer or a failure of engraftment after cell infusion. To accomplish this, we will: 1) characterize more completely the newly established Gaucher L444P mutant mouse; 2) intravenously administer retrovirally and lentivirally transduced hematopoietic progenitors to determine the extent of improved glucocerebrosidase enzyme levels in the tissues of the recipient mutant mice; and, 3) transplant by intrathecal administration ex vivo transduced hematopoietic or neuronal progenitors to determine if these cells will repopulate in brain and express glucocerebrosidase activity. At the completion of this study we will have determined whether lentiviral mediated gene transfer of human GC will result in sustained and improved enzyme levels in tissues, particularly brain, of recipient Gaucher mutant mice.
描述(由申请方提供):神经元病型戈谢病仍然是CNS症状治疗的挑战。一种方法是基因治疗,但是尽管事实上葡萄糖脑苷脂酶(GC)cDNA已经通过逆转录病毒载体成功地转移到正常的鼠和人造血干细胞或通过腺相关病毒载体转移到肌肉细胞,并且转导的鼠细胞成功地移植到小鼠中,但迄今为止进行的三项临床试验导致低水平的基因转移,或输注后植入失败,只有一个例外。使用逆转录病毒、慢病毒和其他载体已经成功地证明了向神经元的基因转移。已证明转导的神经元和造血祖细胞的植入在受体动物的脑中。我们假设,移植造血或神经元祖细胞转导的逆转录病毒和慢病毒载体含有人葡萄糖脑苷脂酶的cDNA。本研究将检验以下假设:移植由含有人葡萄糖脑苷脂酶cDNA的逆转录病毒和慢病毒载体转导的造血或神经元祖细胞将植入受体Gaucher L444 P突变小鼠中并导致酶水平的改善。已经成功地证明了逆转录病毒和慢病毒载体的基因转移到神经元,并且已经在受体动物的脑中实现了转导的神经元和造血祖细胞的植入。然而,尽管在动物模型中取得了成功,但迄今为止进行的三项临床试验通常导致基因转移水平低或细胞输注后植入失败。为了实现这一点,我们将:1)更完整地表征新建立的Gaucher L444 P突变小鼠; 2)静脉内施用逆转录病毒和慢病毒转导的造血祖细胞以确定受体突变小鼠组织中葡萄糖脑苷脂酶水平改善的程度;并且,在本发明中,第三章通过鞘内施用离体转导的造血祖细胞或神经元祖细胞进行移植,以确定这些细胞是否将在脑中重新增殖并表达葡糖脑苷脂酶活性。在本研究完成时,我们将确定慢病毒介导的人GC基因转移是否会导致受体高雪氏突变小鼠组织(特别是脑)中酶水平的持续和改善。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EDWARD I GINNS其他文献
EDWARD I GINNS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EDWARD I GINNS', 18)}}的其他基金
A Novel Orally Administered Macrophage Delivered Gene Therapy for Gaucher Disease
一种新型口服巨噬细胞治疗戈谢病的基因疗法
- 批准号:
7340503 - 财政年份:2006
- 资助金额:
$ 19.88万 - 项目类别:
A Novel Orally Administered Macrophage Delivered Gene Therapy for Gaucher Disease
一种新型口服巨噬细胞治疗戈谢病的基因疗法
- 批准号:
7547743 - 财政年份:2006
- 资助金额:
$ 19.88万 - 项目类别:
A Novel Orally Administered Macrophage Delivered Gene Therapy for Gaucher Disease
一种新型口服巨噬细胞治疗戈谢病的基因疗法
- 批准号:
7752542 - 财政年份:2006
- 资助金额:
$ 19.88万 - 项目类别:
A Novel Orally Administered Macrophage Delivered Gene Therapy for Gaucher Disease
一种新型口服巨噬细胞治疗戈谢病的基因疗法
- 批准号:
7164431 - 财政年份:2006
- 资助金额:
$ 19.88万 - 项目类别:
Novel Orally Administered Macrophage Delivered Gene Ther
新型口服巨噬细胞传递基因疗法
- 批准号:
7022537 - 财政年份:2006
- 资助金额:
$ 19.88万 - 项目类别:
SEARCH FOR DNA MARKERS LINKED TO MANIC DEPRESSIVE ILLNESS IN THE OLD ORDER AMISH
在旧秩序阿米什人中寻找与躁狂抑郁症相关的 DNA 标记
- 批准号:
6111168 - 财政年份:
- 资助金额:
$ 19.88万 - 项目类别:
TRANSGENIC ANIMAL MODELS OF HUMAN INHERITED DISORDERS
人类遗传性疾病的转基因动物模型
- 批准号:
6432827 - 财政年份:
- 资助金额:
$ 19.88万 - 项目类别:
CORRECTION OF INHERITED PROTEIN DEFICIENCEIS BY GENE THERAPY
通过基因疗法纠正遗传性蛋白质缺陷
- 批准号:
6290532 - 财政年份:
- 资助金额:
$ 19.88万 - 项目类别:
CORRECTION OF INHERITED PROTEIN DEFICIENCEIS BY GENE THERAPY
通过基因疗法纠正遗传性蛋白质缺陷
- 批准号:
6111134 - 财政年份:
- 资助金额:
$ 19.88万 - 项目类别:
MOLECULAR GENETICS OF INHERITED NEUROLOGIC AND PSYCHIATRIC DISORDERS
遗传性神经和精神疾病的分子遗传学
- 批准号:
6111135 - 财政年份:
- 资助金额:
$ 19.88万 - 项目类别:
相似海外基金
Say Yes to NO: The Next Generation Scaffolds with Localized and Sustained Nitric Oxide (NO) Delivery for Central Nervous System Regeneration
对“否”说“是”:具有局部和持续一氧化氮 (NO) 输送的下一代支架,用于中枢神经系统再生
- 批准号:
EP/X027198/2 - 财政年份:2024
- 资助金额:
$ 19.88万 - 项目类别:
Fellowship
Strategy to Attack Coronavirus Infections Brain Fog-Central Nervous System Sequelae Using a Novel Patented Technology
利用新型专利技术对抗冠状病毒感染脑雾-中枢神经系统后遗症的策略
- 批准号:
23K10453 - 财政年份:2023
- 资助金额:
$ 19.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune cells protecting from lethal viral infection in the central nervous system
鉴定中枢神经系统免受致命病毒感染的免疫细胞
- 批准号:
22KJ1176 - 财政年份:2023
- 资助金额:
$ 19.88万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Elucidation of metabolic control mechanism by FGF21-mediated central nervous system signaling in neonatal period
阐明新生儿期 FGF21 介导的中枢神经系统信号传导的代谢控制机制
- 批准号:
23K10836 - 财政年份:2023
- 资助金额:
$ 19.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 19.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Central Nervous System Reprogramming of the Control of Blood Pressure Induced by Early Life Stress
早期生活压力引起的血压控制的中枢神经系统重新编程
- 批准号:
10555126 - 财政年份:2023
- 资助金额:
$ 19.88万 - 项目类别:
Central nervous system inflammation due to a high-fat diet and changes in exercise volume - effects on obesity
高脂肪饮食和运动量变化引起的中枢神经系统炎症——对肥胖的影响
- 批准号:
23K10646 - 财政年份:2023
- 资助金额:
$ 19.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
2023 Central Nervous System Injury and Repair Gordon Research Conference and Seminar
2023中枢神经系统损伤与修复戈登研究会议暨研讨会
- 批准号:
10753737 - 财政年份:2023
- 资助金额:
$ 19.88万 - 项目类别:
Maladaptive Remodeling of the Neuromuscular Synapse Following Central Nervous System Injury
中枢神经系统损伤后神经肌肉突触的适应不良重塑
- 批准号:
10569935 - 财政年份:2023
- 资助金额:
$ 19.88万 - 项目类别:
Effects of Central Nervous System Agents on Next Generation Development via Changes in Sperm DNA Methylation
中枢神经系统药物通过精子 DNA 甲基化的变化对下一代发育的影响
- 批准号:
23K19438 - 财政年份:2023
- 资助金额:
$ 19.88万 - 项目类别:
Grant-in-Aid for Research Activity Start-up